RACIAL DIFFERENCES IN EXTRARENAL POTASSIUM METABOLISM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是阐明肾外钾代谢的种族差异的病因。在最近的一项研究中，我们证明了非裔美国人在静脉注射后的血清K+水平往往高于高加索人。据推测，这是由于非裔美国人的Na+K+ATPase泵活动迟缓，这被认为是由丰富的褪黑素前体的非神经元多巴胺介导的。我们之前对卡比多巴--一种非特异性多巴胺合成抑制剂--的研究未能证明这一点，可能是因为它的非特异性阻断。出于这个原因，我们现在开始一项使用多巴胺受体拮抗剂甲氧氯普胺的研究，并将其与卡比多巴和安慰剂进行比较，看看这种种族差异是否被消除了。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to elucidate the etiology of racial differences in extrarenal potassium metabolism. In a recent study, we demonstrated that African Americans tend to have higher serum K+ levels after an IV infusion than do Caucasians. It has been postulated that this is due to sluggish Na+K+ ATPase pump activity in African Americans This is thought to be mediated by non-neuronal dopamine from abundant melatonin precursors. Our previous study with carbidopa - a non-specific dopamine synthesis inhibitor, failed to show this, possibly because of its non-specific blockage. For this reason we are now to embark on a study using a dopamine receptor antagonist, metochlopramide, and compare this to carbidopa and placebo to see if this racial difference is obliterated.